Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability

• Published in: Bioorganic & medicinal chemistry letters 2019-10, Vol.29 (19), p.126604-126604, Article 126604
• Main Authors: Clark, Charles G., Rossi, Karen A., Corte, James R., Fang, Tianan, Smallheer, Joanne M., De Lucca, Indawati, Nirschl, David S., Orwat, Michael J., Pinto, Donald J.P., Hu, Zilun, Wang, Yufeng, Yang, Wu, Jeon, Yoon, Ewing, William R., Myers, Joseph E., Sheriff, Steven, Lou, Zhen, Bozarth, Jeffrey M., Wu, Yiming, Rendina, Alan, Harper, Timothy, Zheng, Joanna, Xin, Baomin, Xiang, Qian, Luettgen, Joseph M., Seiffert, Dietmar A., Wexler, Ruth R., Lam, Patrick Y.S.
• Format: Article
• Language: English
• Subjects: Activated partial thromboplastin time; Anticoagulant; aPTT; Bioavailability; Factor XIa inhibitors; FXIa; Thrombosis
• ISSN: 0960-894X; 1464-3405
• DOI: 10.1016/j.bmcl.2019.08.008

[Display omitted] This manuscript describes the discovery of a series of macrocyclic inhibitors of FXIa with oral bioavailability. Assisted by structure based drug design and ligand bound X-ray crystal structures, the group linking the P1 moiety to the macrocyclic core was modified with the goal of reducing H-bond donors to improve pharmacokinetic performance versus 9. This effort resulted in the discovery of several cyclic P1 linkers, exemplified by 10, that are constrained mimics of the bioactive conformation displayed by the acrylamide linker of 9. These cyclic P1 linkers demonstrated enhanced bioavailability and improved potency.